Journal of Medical Academics

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  6 (2023)
Volume  5 (2022)
Volume  4 (2021)
Volume  3 (2020)
Volume  2 (2019)
Volume  1 (2018)
Related articles

VOLUME 1 , ISSUE 2 ( July-December, 2018 ) > List of Articles

REVIEW ARTICLE

Road to Cancer Cure–So Near and Yet So Far

Ravindra Chaturvedi

Keywords : Cancer, CAR- T cell, Checkpoint Inhibitors, Immunotherapy, Monoclonal antibodies

Citation Information : Chaturvedi R. Road to Cancer Cure–So Near and Yet So Far. Journal of Medical Academics 2018; 1 (2):94-101.

DOI: 10.5005/jp-journals-10070-0020

License: NA

Published Online: 01-12-2018

Copyright Statement:  NA


Abstract

Cancer has become a leading cause of mortality worldwide, next only to cardiovascular diseases. Patients who develop cancer are known to exhibit several genomic alterations. Conventional therapies for the management of cancer have their own limitations. Immunotherapy is coming up as a promising new option for millions of patients who are suffering from end stage metastasis or refractory malignancies. To this end, the goal of cancer immunotherapy is to recruit and potentiate immune cells that can generate a robust and long lasting immune response and specifically target the cancer cells with minimum damage to normal cells. These treatment strategies, when used either alone or in combination, are known to significantly effect tumor growth and have even produced cures. In this brief review, some of the most popular cancer immunotherapy approaches shall be reviewed. Recent data from clinical trials suggest that combining more than one immunotherapy mechanisms, in conjunction with other treatment options like chemotherapy, radiotherapy and targeted therapy , may be the way forward to a complete cancer cure.

PDF Share
  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov;68(6):394-424.
  2. Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clinical therapeutics. 2016;38(7):1551-1566.
  3. Kokate R. A systematic overview of cancer immunotherapy: an emerging therapy; I Pharm Pharmacol Int J. 2017;5(2): 31-35.
  4. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. InSeminars in cancer biology 2015 Dec 1 (Vol. 35, pp. S185-S198).
  5. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002 Jun;71(6):907-920.
  6. Iranzo J, Martincorena I, Koonin EV. Cancer-mutation network and the number and specificity of driver mutations. Proceedings of the National Academy of Sciences. 2018;115(26):E6010-E6019.
  7. Ventola C L . Cancer Immunotherapy, Part 1: Current Strategies and Agents . P T. 2017 Jun; 42(6):375-383.
  8. Ming L, Fukun G. Recent updates on cancer immunotherapy. Precision Clinical Medicine, 2018;1(2):65-74.
  9. Clinical Trials.gov ; Cancer Immunotherapy Trials. [Cited in Jan 2019]. Available from: https://clinicaltrials.gov/ct2/res ults?term=cancer+immunotherapy and Search=Search.
  10. Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Annals of translational medicine. 2016 Jul;4(14).
  11. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68.
  12. Restifo NP, Dudley NE, Steven A. Rosenberg. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology. 2012 Mar 22;12(4):269-281 .
  13. Houot R, Schultz LM, Marabelle A, Kohrt H. T-cell.based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer immunology research. 2015 Oct 1;3(10):1115- 1122.
  14. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-totreat analysis and efficacy after failure to prior immunotherapies. Clinical Cancer Research. 2013 Sep 1;19(17):4792-800.
  15. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumorinfiltrating lymphocytes in metastatic melanoma patients. Clinical Cancer Research. 2012;18(24):6758-6770.
  16. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nature Reviews Cancer. 2016 Sep;16(9):566-581.
  17. Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell. 2018 Mar;9(3):254-266.
  18. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):126-129.
  19. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, et al. NY-ESO-1.specific TCR.engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature medicine. 2015 Aug;21(8):914-921.
  20. Hartmann J, Schüßler Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells.challenges and opportunities in translating innovative treatment concepts. EMBO molecular medicine. 2017 Sep 1;9(9):1183-1197.
  21. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine. 2014;371(16):1507-1517.
  22. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor.positive T cells in patients with neuroblastoma. Blood. 2011 Dec 1;118(23):6050-6056.
  23. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumorspecific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nature Medicine [Internet]. Springer Nature; 2008 Nov;14(11):1264-12670.
  24. Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-oncology. 2018 Mar 2;20(11):1429-1438.
  25. Germain RN, Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol. 1999;17:467-522.
  26. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. American journal of clinical oncology. 2016;39(1):98-106.
  27. Chen L and Xue Han. Anti.PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9): 3384-3391.
  28. Topalian S L , Hodi F S . Safety, Activity, and Immune Correlates of Anti.PD-1 Antibody in Cancer. N Engl J Med. 2012 Jun 28;366(26):2443-2454.
  29. LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 pathway in tumor therapy. The Journal of Immunology. 2018;200(2):375-383.
  30. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;26(359):1350-1355.
  31. Dashnamoorthy R, Chen B, Galera P, Chang H, Beheshti A, Ghosh S, Evens AM. The Immune Checkpoint Receptors PD-1, PD-L1, TIM-3 and LAG-3 in Lymphoma: Tumor Cell and Tumor Infiltrating Lymphocyte (TIL) Expression, Patient Prognostication, and Identification of Rational Therapeutic Targets. Blood 2017;130:2750.
  32. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, et al. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. Frontiers in Immunology [Internet]. Frontiers Media SA; 2018 Feb 27;9:385.
  33. Chunqing G, Masoud HM, John RS, Devanand S, Paul BF, Xiang-Yang W. Therapeutic Cancer Vaccines: Past, Present and Future. Adv Cancer Res. 2013;119:421-475.
  34. Olivera J. Finn. Vaccines for Cancer Prevention: A Practical and feasible approach to the Cancer Epidemic . Cancer Immunol Res. 2014 Aug;2(8):708-713.
  35. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present, and future. InAdvances in cancer research 2013 Jan 1 Vol. 119, pp. 421-475.
  36. Santos PM, Butter.eld LH. Dendritic Cell-Based Cancer Vaccines. J Immunol 2018;200:443-449.
  37. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-277.
  38. Subramaniam D S. Novel Approaches to Cancer Immunotherapy. Discov Med 2016 Apr; 21(116):267-274.
  39. Thomas S, Prendergast GC. Cancer Vaccines: A Brief Overview. In Sunil Thomas (ed.), Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases, Methods in Molecular Biology, vol. 1403, April 2016.
  40. Nemunaitis J . Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Clinical Evidence of the Immunologic Mechanism of Action (MOA). Cancer- Immunotherapy: Harnessing Gene Therapy To Improve Anti-Tumor Effect. 2012 May; 20 (Supplement 1), S131.
  41. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nature reviews Clinical oncology. 2014 Sep;11(9):509-524.
  42. Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. Journal for immunotherapy of cancer. 2018 Dec;6(1):140.
  43. Becker N and Benhar I. Antibody-Based Immunotoxins for the Treatment of Cancer. Antibodies 2012;1:39-69.
  44. Coulson A, Levy A, Gossell-Williams M. Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations. West Indian Med J. 2014 Oct;63(6):650-654.
  45. Ardolino M, Hsu J, Raulet D H. Cytokine treatment in cancer immunotherapy. Oncotarget. 2015 Aug 14;6(23): 19346- 19347.
  46. Conlon KC, Miljkovic , Waldmann TA. Cytokines in the Treatment of Cancer. J Interferon Cytokine Res . 2019 Jan;39(1): 6-21.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.